{"id":"NCT01410474","sponsor":"Novartis","briefTitle":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan","officialTitle":"A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2011-08-05","resultsPosted":"2014-09-22","lastUpdate":"2014-09-22"},"enrollment":341,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Bacterial Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal ACWY conjugate vaccine","otherNames":[]}],"arms":[{"label":"2-18 years","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the immunogenicity and safety of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 2 to 18 years in Taiwan.","primaryOutcome":{"measure":"Percentage of Overall Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination","timeFrame":"Day 1 and Day 29","effectByArm":[{"arm":"Overall (2 to 18 Years)","deltaMin":83,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["China"]},"refs":{"pmids":["25075804"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":173},"commonTop":["Injection site pain","Injection site erythema","Injection site induration","Myalgia","Malaise"]}}